CCL20及其受体CCR6在大肠癌中的表达及其意义

 目的　观察趋化因子CCL20及其受体CCR6在大肠癌组织中的表达及其与临床病理特征的关系，探讨其对大肠癌肝转移的影响。方法　采用荧光定量反转录聚合酶链反应（Q-RT-PCR）方法检测123例行大肠癌根治术患者的大肠癌组织、正常肠黏膜组织及其中19例大肠癌肝转移组织及肝转移灶旁肝组织中CCL20和CCR6 mRNA表达情况。结果　趋化因子受体CCR6在大肠癌组织及相应的肝转移组织中呈高表达（分别为2.100±0.216，1.530±0.172），与正常肠黏膜组织（0.636±0.190）比较，表达水平差异有统计学意义（t值分别为-3.778、-1.598，均P＜0.05）；肝转移灶旁组织（0.597±0.247）与正常肠黏膜组织比较，表达水平差异无统计学意义（t＝-0.200、P＞0.05）。趋化因子CCL20 mRNA在大肠癌肝转移组织及肝转移灶旁组织中高表达（分别为1.780±0.126，3.461±0.134），与正常肠黏膜组织（0.759±0.072）比较，表达水平差异有统计学意义（t值分别为-2.087、-5.607，P＜0.05）。在大肠癌肝转移组织中，CCL20 mRNA的表达量明显高于无大肠癌肝转移组织，差异有统计学意义（t＝-8.357，P＜0.05）。CCR6／ CCL20轴的mRNA表达与患者性别（U值分别为0.360、0.530）、年龄（U值分别为0.089、0.436）及肿瘤分期（U值分别为0.063、0.129）无相关性（均P＞0.05），而CCR6及CCL20 mRNA的表达与大肠癌的远处转移（U值分别为0.002、0.032）及淋巴结转移（U值分别为0.013、0.007）有一定的相关性（均P＜0.05）。结论　CCR6／CCL20信号轴在大肠癌组织中的表达与大肠癌肝转移的形成有相关性。

Expression of chemokine CCL20 and its receptor CCR6 in colorectal cancer and their clinical significance

Objective　To evaluate and compare the expression of chemokine CCL20 and its receptor CCR6 in colorectal cancer tissue, normal colon mucosa, colorectal liver metastases and adjacent nontumorous liver tissues to elucidate their impact on the carcinogenesis and progression of colorectal liver metastasis. Methods　Chemokine expression was analyzed by Q-RT-PCR in 123 cases of colorectal cancer tissue and 19 cases of colorectal liver metastases and corresponding adjacent nontumorous liver tissues, respectively. Expressions of its receptors CCR6 was analyzed by Q-RT-PCR and in the same cases of colorectal cancer and corresponding adjacent nontumorous liver tissues. Results　The expression levels of CCR6 mRNA in colorectal cancer tissue (2.100±0.216) (t = -3.778, P < 0.05) and in the tissue of colorectal liver metastases (1.530±0.172) (t =- 1.598, P < 0.05) were higher than that in normal colon mucosa (0.636±0.190). The expression level of CCR6 mRNA in colerectal liver metastases was compared between adjacent nontumorous liver tissues(t = -0.200) and normal colon mucosa. A statistically relevant (P < 0.05) upregulation of the expression for the expression of CCL20 mRNA was higher in the tissue of colorectal liver metastases (1.780±0.126) (t = -2.087) and adjacent nontumorous liver tissues (3.461±0.134) (t = -5.607) than normal colon mucosa (0.759±0.072). A statistically relevant (P < 0.05) upregulation of the expression of CCL20 mRNA was higher in the tissue of colorectal liver metastases than adjacent nontumorous liver metastases tissues (t = -8.357). A statistically relevant (P > 0.05) of the expression of CCR6/CCL20 mRNA was no significant correlation the sex of the patient (CCR6, U = 0.360; CCL20 U = 0.530), age (CCR6, U = 0.089; CCL20 U = 0.436) and TNM stages(CCR6, U = 0.063; CCL20 U = 0.129). while CCR6 and CCL20 mRNA expression in colorectal carcinoma and distant metastasis CCR6, U = 0.002; CCL20 U = 0.032) and lymph node metastasis (CCR6, U = 0.013; CCL20 U = 0.007) have some correlation (P < 0.05). Conclusion　The findings strongly suggest an association between CCL20/CCR6 expression in human colorectal cancer and the promotion of colorectal liver metastasis.